Multi-centre, Open-label, Single Arm, Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacogenomics and Efficacy of a Single Intravenous Dose of Spesolimab in Patients With Active Generalized Pustular Psoriasis
Latest Information Update: 23 Aug 2023
At a glance
- Drugs Spesolimab (Primary)
- Indications Pustular psoriasis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 07 Mar 2019 Accoding to the Boehringer Ingelheim media release, Professor Herve Bachelez is the principal investigator for this trial.
- 07 Mar 2019 Accoding to the Boehringer Ingelheim media release, data from this trial were presented at the American Academy of Dermatology (AAD) annual meeting.
- 07 Mar 2019 Accoding to the Boehringer Ingelheim media release, new data from this trial were published in the New England Journal of Medicine.